# Neurophth

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurophth

- Industry: Biotechnology
- Headquarters: Wuhan, China
- Website: www.neurophth.com
- Total disclosed funding: $240M
- Latest round: Series C (Aug 9, 2023)
- Investors on record: 21

## About

Based in Wuhan, China and established in 2016, Neurophth is a biotechnology company that engages in the R&D and production of new drugs for ophthalmic diseases. The company was established by Professor Bin Li, who has over 20 years of clinical practice and academic experience at Tongji Hospital of Tongji Medical College. Moreover, Professor Bin Li characterized the AAV vectors in inherited blindness. The company has three subsidiaries in Shanghai, Suzhou, and US. And it has a production base of 8,000 square meters. In 2020, its product, NFS-01 received the FDA certification and received NMPA clinical IND application for acceptance in January 2021. In 2021, it raised CNY 400 million in series B funding. In August 2023, Neurophth raised approximately CNY 700 million in series C+ funding.

The company developed more than 10 product pipelines for ophthalmic diseases based on the validated AAV platform. Its product, NFS-01 and NFS-02 are treated for Leber's Hereditary optic neuropathy, which has been into clinical three phases, and clinical two phases, respectively. Its product, NFS-04 is treated for optic neuropathy injury. And its product, NFS-05, is treated for dominantly inherited optic atrophy.

## Funding rounds

- Series C, Aug 9, 2023, $97M — TTGG Ventures, Yangtze River Industry Fund, CMB International Asset Management, CS Capital, Jinkong Fund Management, Wuhan Optical Valley Financial Holding Group, Optics Valley Industrial Investment Fund Management, Wuhan High-tech Industry Investment Private Fund Management
- Series C, Nov 22, 2021, $63M — Hong Shan, CMB International Asset Management, Sunshine Insurance, Riverhead Capital, CMG-SDIC Capital Management
- Series B, Feb 9, 2021, $62M — Oriza Holdings, Harvest Capital, InnoVision Capital, Shanghai Growth Investment, Grand Mount Capital
- Series A, Apr 8, 2020, $18M — Hong Shan, NLVC, Fosun International
- Angel, Aug 16, 2018 — NLVC, Shenzhen Huada Gene Technology Co., Ltd., Bohe Angel Fund

## Investors

- NLVC (https://capitalatlas.ai/funds/nlvc) — Angel, Series A
- Shenzhen Huada Gene Technology Co., Ltd. — Angel
- Bohe Angel Fund — Angel
- Hong Shan — Series A, Series C
- Fosun International (https://capitalatlas.ai/funds/fosun-international) — Series A
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series B
- Harvest Capital — Series B
- InnoVision Capital (https://capitalatlas.ai/funds/innovision-capital) — Series B
- Shanghai Growth Investment (https://capitalatlas.ai/funds/shanghai-growth-investment) — Series B
- Grand Mount Capital (https://capitalatlas.ai/funds/grand-mount-capital) — Series B
- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series C
- Sunshine Insurance — Series C
- Riverhead Capital (https://capitalatlas.ai/funds/riverhead-capital) — Series C
- CMG-SDIC Capital Management — Series C
- TTGG Ventures (https://capitalatlas.ai/funds/ttgg-ventures) — Series C
- Yangtze River Industry Fund (https://capitalatlas.ai/funds/yangtze-river-industry-fund) — Series C
- CS Capital — Series C
- Jinkong Fund Management (https://capitalatlas.ai/funds/jinkong-fund-management) — Series C
- Wuhan Optical Valley Financial Holding Group — Series C
- Optics Valley Industrial Investment Fund Management (https://capitalatlas.ai/funds/optics-valley-industrial-investment-fund-management) — Series C
- Wuhan High-tech Industry Investment Private Fund Management (https://capitalatlas.ai/funds/wuhan-high-tech-industry-investment-private-fund-management) — Series C